[Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion]

Bull Cancer. 2020 Nov;107(11):1085-1086. doi: 10.1016/j.bulcan.2020.09.009. Epub 2020 Oct 21.

[Article in French]

Authors

Matthieu Delaye¹, Manuel Rodrigues²

Affiliations

¹ Hôpital Tenon, service d'oncologie médicale et de thérapie cellulaire, 4, rue de la Chine, 75020 Paris, France; Association pour l'enseignement et la recherche des internes en oncologie (AERIO), 149, avenue du Maine, 75014 Paris, France.
² PSL Research University, institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France; PSL Research University, institut Curie, Inserm U830, 26, rue d'Ulm, 75005 Paris, France. Electronic address: [email protected].

PMID: 33169692
DOI: 10.1016/j.bulcan.2020.09.009

No abstract available

Publication types

Letter
News

MeSH terms

Adult
Benzamides / adverse effects
Benzamides / therapeutic use*
Child
Drug Approval*
France
Humans
Indazoles / adverse effects
Indazoles / therapeutic use*
Membrane Glycoproteins / genetics
Neoplasms / drug therapy*
Neoplasms / genetics
Neoplasms / mortality
Oncogene Proteins, Fusion*
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Pyrazoles / adverse effects
Pyrazoles / therapeutic use*
Pyrimidines / adverse effects
Pyrimidines / therapeutic use*
Receptor, trkA / genetics
Receptor, trkB / genetics
Receptor, trkC / genetics

Substances

Benzamides
Indazoles
Membrane Glycoproteins
NTRK1 protein, human
NTRK3 protein, human
Oncogene Proteins, Fusion
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
Receptor, trkA
Receptor, trkB
Receptor, trkC
tropomyosin-related kinase-B, human
entrectinib
larotrectinib